Mochida Pharmaceutical Co., Ltd.
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2016/01/31 | ¥101.11 | ¥90.22 | -10.8% |
| 2015/07/30 | ¥43.46 | ¥80.56 | +85.4% |
| 2015/05/14 | ¥28.84 | ¥26.65 | -7.6% |
| 2015/01/29 | ¥63.24 | ¥84.87 | +34.2% |
Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
Vanguard International Stock Index-Total Intl Stock Indx
|
324.7K | 0.00% | |
|
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund
|
193.9K | 0.00% | |
|
iShares Core MSCI EAFE ETF
|
134.9K | 0.00% | |
|
iShares MSCI EAFE Small Cap ETF
|
66.8K | -1.62% | |
|
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index
|
63.9K | +9.42% | |
|
iShares Core MSCI Total International Stock ETF
|
62.8K | 0.00% |
Dividend History 1Years Growth
Updated 2026/10/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥83 | +3.1% |
| 2025 | ¥80 | 0.0% |
| 2024 | ¥80 | 0.0% |
| 2023 | ¥80 | -11.1% |
| 2022 | ¥90 | - |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥110,179M | ¥103,261M | ¥102,885M | ¥105,159M |
| Gross Profit | ¥59,553M | ¥55,114M | ¥52,070M | ¥53,787M |
| Operating Income | ¥14,392M | ¥8,507M | ¥5,803M | ¥8,126M |
| Pretax Income | ¥14,591M | ¥9,044M | ¥6,162M | ¥8,055M |
| Net Income | ¥10,569M | ¥6,649M | ¥4,547M | ¥5,685M |
| EPS | ¥277.39 | ¥178.93 | ¥126.80 | ¥160.36 |
| Operating Margin | 13.06% | 8.24% | 5.64% | 7.73% |
| Balance Sheet | ||||
| Total Assets | ¥163,139M | ¥158,831M | ¥158,800M | ¥160,121M |
| Total Equity | ¥128,643M | ¥126,773M | ¥127,965M | ¥130,693M |
| Total Liabilities | ¥34,496M | ¥32,058M | ¥30,835M | ¥29,428M |
| Cash | ¥48,415M | ¥47,010M | ¥33,290M | ¥45,154M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 78.85% | 79.82% | 80.58% | 81.62% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥7,459M | ¥7,297M | -¥7,480M | ¥9,354M |
| Investing CF | -¥2,007M | -¥2,949M | ¥74M | ¥17,355M |
| Financing CF | -¥5,956M | -¥6,884M | -¥6,393M | -¥2,865M |
| Free CF | ¥4,363M | ¥5,131M | -¥9,776M | ¥7,194M |
| Efficiency | ||||
| ROE | 8.22% | 5.24% | 3.55% | 4.35% |
| ROA | 6.48% | 4.19% | 2.86% | 3.55% |
Latest IR Information
-
Notice Regarding Status of Treasury Stock Acquisition
Target is common shares; number of shares acquired is 57,400 shares; total acquisition amount is 186,619,000 yen. Acquisition period is 2026/9/1–2026/9/30, method is market purchase. At the board resolution on 2026/3/30, an upper limit of 530,000 shares, an upper limit...
Read more -
Notice Regarding Share Buyback Status
The target shares for buyback are our common shares, total 82,000 shares, aggregate purchase price 264,719,000 yen. Buyback period is from August 1, 2026 to August 31, 2026 (on a contracted basis), conducted via market purchases. Based on the Board...
Read more -
First Quarter Financial Summary for Period Ending March 2027 (Japanese GAAP) (Consolidated)
In the first quarter of the fiscal year ending March 2027, net sales were 31.719 billion yen, up 19.1% year over year. Operating income was 3.564 billion yen (+38.5%), ordinary income was 4.187 billion yen (+50.5%), and net income attributable...
Read more -
Notice regarding the status of share buyback
The acquisition target is common stock, total number of shares acquired is 90,600 shares, total acquisition value is 286,404,500 yen (286,404,500 yen), and the acquisition period is from 2026/7/1 to 2026/7/31, with the method being market purchases. Cumulative to date...
Read more -
Notification Regarding Share Buyback
Engaged in share buyback. Targets 60,600 ordinary shares, total amount 192,845,500 yen, period 2026/6/1–2026/6/30, method is market purchase (Tokyo Stock Exchange).
Read more
Latest News (5 items)
Company Information
About
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypertension; Treprospermid, for pulmonary hypertension associated with ulcerative lung disease; Uris, for gout and hyperuricemia; and Clorox, for ulcerative colitis; Epadel for hyperlipidemia and obstructive arteriosclerosis; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker antihypertensive drug; Heparin Na anticoagulants; and Onboard, ulcerative colitis and Crohn's disease treatment agents. In addition, it develops medical devices, including dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for adhesion prevention material. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products, as well as academic research and marketing. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Shinjuku, Japan.
